ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0473

Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome

Mingce Zhang1, Remy Cron2, Devin Absher3, Prescott Atkinson1, Winn Chatham1 and Randy Cron1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3HudsonAlpha Institute for Biotechnology, Huntsville, AL

Meeting: ACR Convergence 2020

Keywords: cytokines, Cytotoxic Cells, macrophage activation syndrome, Natural Killer Cells, T Cell

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Pediatric Rheumatology – Basic Science (0469–0473)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Cytokine storm syndrome (CSS), also known as macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH), is a life threatening condition that commonly presents with unremitting fever and shock like multi-organ dysfunction (MOD). Laboratory studies show pancytopenia, elevated liver enzymes, elevated ferritin, and hemophagocytosis. Familial forms of HLH result from homozygous defects in genes involved in perforin mediated cytolysis by NK cells and CD8 T cells. As many as 30-40% of CSS patient cohorts studied have heterozygous defects in the same HLH genes resulting in decreased cytolytic function, prolonged interaction with antigen presenting cells, and subsequent increased pro-inflammatory cytokines resulting in MOD. Since NK cell dysfunction is common in CSS, there are likely other genes that contribute to CSS via decreased cytolysis. Using gene sequencing, mutations in potentially novel HLH genes present in 2 or more CSS patients were explored.

Methods: Pediatric and adult patients with CSS at UAB were screened for genetic mutations, potentially contributing to CSS, via whole genome sequencing or a commercial immunodeficiency exomic genetic panel of 207 genes. Four patients were noted to have mutations in the guanine nucleotide exchange factor DOCK8 critical to NK cell function. DOCK8 mutations from this CSS cohort, or wild-type (WT) sequence controls, were introduced exogenously into human NK-92 NK cell lines by foamy virus (FV) transduction. Alternatively, the endogenous NK-92 DOCK8 genes were cut and repaired to express WT sequence or patient derived DOCK8 mutations by CRISPR/Cas9 technology. WT and mutant DOCK8 expressing NK-92 cells were incubated with K562 target cells and compared for cytolytic activity, degranulation (CD107a), and cytokine [interferon-g (IFNg), tumor necrosis factor (TNF)] production by flow cytometry.

Results: Two CSS patients were identified with rare heterozygous DOCK8 mutations, and 2 others with CSS were noted to have the same DOCK8 polymorphism (c.187G >A, p.Asp63Asn) present in 12% of the population (Table). One of the rare mutations was missense (c.782C >T, p.Ala261Val – novel), and one was a splice acceptor variant (c.54-1G >T, 0.03%). The novel DOCK8 mutant consistently decreased NK cell lytic activity when introduced by either CRISPR/Cas9 (n=2) or FV (n=3, decreased by ~50% compared to WT, p=0.007) (Fig. 1). Similarly, the novel mutant decreased degranulation by >50% (n=3, p=0.013) (Fig. 2). During the incubation of the NK-92 cells with K562 targets, NK cells expressing the novel DOCK8 mutant increased expression of IFNg and TNF by >200% (p=0.019 & p=0.003, respectively). The DOCK8 polymorphism decreased lysis and degranulation to a lesser degree. The DOCK8 splicing mutation disrupted RNA splicing by an exon trapping assay and a novel assay developed in the lab.

Conclusion: Heterozygous mutations in DOCK8, a novel CSS associated gene, likely contribute to CSS pathology through a partial dominant-negative or hypomorphic effect resulting in decreased cytolysis and increased pro-inflammatory cytokine production.

Table. DOCK8 rare mutations and polymorphisms identified in CSS patients.

Figure 1. Cytolytic activity of patient #1 DOCK8 missense mutation in NK-92 cells. NK-92 cells were transduced with WT or patient mutation DOCK8-expressing FV and incubated with K562 target cells. A. K562 lysis detected by near-IR fluorescence at 2 E:T ratios. B. N=3, means +/- SEMs.

Figure 2. Degranulation of patient #1 DOCK8 missense mutation in NK-92 cells. NK-92 cells were transduced with WT or patient mutation DOCK8-expressing FV and incubated with K562 target cells. A. NK-92 cell degranulation detected by CD107a surface expression at 3 time points. B. N=3, means +/- SEMs.


Disclosure: M. Zhang, None; R. Cron, None; D. Absher, None; P. Atkinson, None; W. Chatham, Sobi, 2, 5; R. Cron, Sobi, 2, 5, 8, Pfizer, 5, Novartis, 5.

To cite this abstract in AMA style:

Zhang M, Cron R, Absher D, Atkinson P, Chatham W, Cron R. Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/characterization-of-dock8-as-a-novel-gene-associated-with-cytokine-storm-syndrome-2/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-dock8-as-a-novel-gene-associated-with-cytokine-storm-syndrome-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology